234 related articles for article (PubMed ID: 29620420)
1. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
[TBL] [Abstract][Full Text] [Related]
2. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
Crawford TD; Vartanian S; Côté A; Bellon S; Duplessis M; Flynn EM; Hewitt M; Huang HR; Kiefer JR; Murray J; Nasveschuk CG; Pardo E; Romero FA; Sandy P; Tang Y; Taylor AM; Tsui V; Wang J; Wang S; Zawadzke L; Albrecht BK; Magnuson SR; Cochran AG; Stokoe D
Bioorg Med Chem Lett; 2017 Aug; 27(15):3534-3541. PubMed ID: 28606761
[TBL] [Abstract][Full Text] [Related]
4. An Advanced Tool To Interrogate BRD9.
Karim RM; Schönbrunn E
J Med Chem; 2016 May; 59(10):4459-61. PubMed ID: 27120693
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain biology and drug discovery.
Zaware N; Zhou MM
Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
[TBL] [Abstract][Full Text] [Related]
7. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
Remillard D; Buckley DL; Paulk J; Brien GL; Sonnett M; Seo HS; Dastjerdi S; Wühr M; Dhe-Paganon S; Armstrong SA; Bradner JE
Angew Chem Int Ed Engl; 2017 May; 56(21):5738-5743. PubMed ID: 28418626
[TBL] [Abstract][Full Text] [Related]
8. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.
Clark PG; Vieira LC; Tallant C; Fedorov O; Singleton DC; Rogers CM; Monteiro OP; Bennett JM; Baronio R; Müller S; Daniels DL; Méndez J; Knapp S; Brennan PE; Dixon DJ
Angew Chem Int Ed Engl; 2015 May; 54(21):6217-21. PubMed ID: 25864491
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.
Song LT; Tu J; Liu RR; Zhu M; Meng YJ; Zhai HL
J Biomol Struct Dyn; 2019 Jul; 37(11):2970-2979. PubMed ID: 30058436
[TBL] [Abstract][Full Text] [Related]
10. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
[TBL] [Abstract][Full Text] [Related]
12. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
13. Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
Clegg MA; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Leveridge M; Lindon M; Liwicki GM; Michon AM; Molnar J; Rioja I; Soden PE; Theodoulou NH; Werner T; Tomkinson NCO; Prinjha RK; Humphreys PG
J Med Chem; 2020 Jun; 63(11):5816-5840. PubMed ID: 32410449
[TBL] [Abstract][Full Text] [Related]
14. The bromodomain: from epigenome reader to druggable target.
Sanchez R; Meslamani J; Zhou MM
Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
[TBL] [Abstract][Full Text] [Related]
15. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
16. Development of chemical probes for the bromodomains of BRD7 and BRD9.
Clark PG; Dixon DJ; Brennan PE
Drug Discov Today Technol; 2016 Mar; 19():73-80. PubMed ID: 27769361
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
Karim RM; Chan A; Zhu JY; Schönbrunn E
J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9).
Basuroy T; Dreier M; Baum C; Blomquist T; Trumbly R; Filipp FV; de la Serna IL
Pigment Cell Melanoma Res; 2023 Jan; 36(1):19-32. PubMed ID: 36112085
[TBL] [Abstract][Full Text] [Related]
19. Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay.
Lu T; Hu JC; Lu WC; Han J; Ding H; Jiang H; Zhang YY; Yue LY; Chen SJ; Jiang HL; Chen KX; Chai HF; Luo C
Acta Pharmacol Sin; 2018 Sep; 39(9):1544-1552. PubMed ID: 29795359
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
